Drug Type Shared antigen vaccine, Therapeutic vaccine |
Synonyms ADXS HPV, ADXS11-001-vaccine, Anal-cancer-vaccine-Advexis + [13] |
Target |
Action inhibitors |
Mechanism E7 inhibitors(HPV E7 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Cervical Carcinoma | Phase 3 | United States | 15 Dec 2015 | |
Locally Advanced Cervical Carcinoma | Phase 3 | Argentina | 15 Dec 2015 | |
Locally Advanced Cervical Carcinoma | Phase 3 | Brazil | 15 Dec 2015 | |
Locally Advanced Cervical Carcinoma | Phase 3 | Canada | 15 Dec 2015 | |
Locally Advanced Cervical Carcinoma | Phase 3 | Chile | 15 Dec 2015 | |
Locally Advanced Cervical Carcinoma | Phase 3 | Malaysia | 15 Dec 2015 | |
Locally Advanced Cervical Carcinoma | Phase 3 | Mexico | 15 Dec 2015 | |
Locally Advanced Cervical Carcinoma | Phase 3 | Poland | 15 Dec 2015 | |
Locally Advanced Cervical Carcinoma | Phase 3 | Russia | 15 Dec 2015 | |
Locally Advanced Cervical Carcinoma | Phase 3 | Serbia | 15 Dec 2015 |
Phase 1 | 12 | (Axalimogene Filolisbac 1x10^9 Cfu) | oevcitnpsq = vltmsbvxsh otoobdqslf (wmvycofurz, efkhgwuzll - otdymeujyz) View more | - | 20 May 2024 | ||
(Axalimogene Filolisbac 5x10^9 Cfu) | oevcitnpsq = lxdhdvfecu otoobdqslf (wmvycofurz, gwcxyixtfd - wrjtufyfdj) View more | ||||||
Phase 1/2 | 75 | (Part A Escalation (Cervical): 1×10^9 CFU ADXS11-001/ 3 mg/kg MEDI4736) | rrdfdfktkv = zjiousvesj opxbocemnm (mmzumhqltu, nujihyuxsb - frljtlrjme) View more | - | 20 Mar 2023 | ||
(Part A Escalation (Cervical and Head and Neck): 1×10^9 CFU ADXS11-001/ 10 mg/kg MEDI4736) | rrdfdfktkv = dqxqrtgdat opxbocemnm (mmzumhqltu, wtjaazjpmf - aqhqdvkyiw) View more | ||||||
Phase 2 | 36 | dfhkuovkvt = vlthvsdsyi zdbokzgmfj (botcdjkhhc, vghqwslhaj - gzvfviqjrg) View more | - | 20 Mar 2023 | |||
Phase 3 | 110 | Placebo (Placebo) | tnqjqjezsv = dweamtyotm rytxnagdhh (hbjrnvakxc, mmvvicmxbd - zyptkbavnc) View more | - | 14 Mar 2023 | ||
(ADXS11-001) | tnqjqjezsv = ytbroaobyf rytxnagdhh (hbjrnvakxc, ullckqoris - ccpyyyisam) View more | ||||||
Phase 2 | 54 | vwbmefjnku = vrwrwtmgmx aqdclmjugb (crqsyslwdv, xdumopzkxu - otkxgaijax) View more | - | 11 Sep 2020 | |||
Phase 2 | 50 | vdbhvscqgf(wvaimlaywh) = npfjqoicdt mwkqubxzqu (idmpoupkrx ) View more | - | 01 Sep 2020 | |||
NCT02399813 (Pubmed) Manual | Phase 2 | 29 | kdvqjsubjb(qnsgzkilmh) = ymyxnyvtol uvwektagsh (zimlbolkcy ) View more | Negative | 14 Apr 2020 | ||
Phase 2 | Uterine Cervical Cancer Maintenance | 29 | hzryswqhgz(inybfjxclu) = alkvwinrzp dsfckvlbnc (lvvyblpkxu ) View more | Positive | 20 May 2016 | ||
Phase 1 | Uterine Cervical Cancer HPV-E7 tumor antigen | 6 | ADXS11-001 5x10^9 CFU | wfmqncuvrk(pgxzxsyjbi) = ujqlywqdog atgjtjrczv (ozouyodqrc ) View more | Positive | 04 Nov 2015 | |
Phase 1 | 10 | Lm-LLO-HER2/neu | rzvulwjvuf(xmjxocxmdm) = yzwmqjrhdq fmnurdsthj (bbtvxbeodl ) View more | - | 01 Aug 2015 |